Hillsdale Investment Management Inc. Purchases Shares of 193,850 Arrowhead Pharmaceuticals, Inc. $ARWR

Hillsdale Investment Management Inc. purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 193,850 shares of the biotechnology company’s stock, valued at approximately $12,870,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $25,000. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $29,000. First Horizon Corp purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $32,000. WPG Advisers LLC boosted its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 431 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 471 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the sale, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 36,065 shares of company stock valued at $2,554,562. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $77.91 on Friday. The stock has a market cap of $10.97 billion, a P/E ratio of -36.24 and a beta of 1.28. The company has a fifty day simple moving average of $69.56 and a 200-day simple moving average of $64.39. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $82.26. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.75 EPS. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ARWR. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. Weiss Ratings cut shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Finally, Sanford C. Bernstein lifted their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $87.80.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.